药明康德完成2025年第二轮人民币10亿元A股回购方案，回购股份将全部注销 | Bilingual News

（来源：）

转自：药明康德

上海，2025年8月28日，为全球医药及生命科学行业提供全方位、一体化新药研发和生产服务的能力和技术平台公司——无锡药明康德新药开发股份有限公司（股票代码：603259.SH/2359.HK）近日宣布，为提升股东价值，已完成今年第二轮人民币10亿元A股回购方案，并将实施相关股份的全部注销：

2025年4月29日，公司股东大会审议通过了本次人民币10亿元的A股回购及注销计划，旨在积极维护公司价值及股东权益。

2025年6月26日至2025年8月26日期间，公司回购A股股份总计11,860,809股，占截至2025年8月27日公司总股本的0.40%。公司计划于2025年8月28日将本次回购的A股股份全部注销。

今年以来，药明康德已累计完成人民币20亿元的A股回购，且所有回购股份将全部注销。公司今年已实施的回购股份及现金分红合计达到人民币58.4亿元，占公司2024年归母净利润的60%以上。

关于药明康德

药明康德（股票代码：603259.SH/2359.HK）是全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者，致力于通过提供一体化、端到端的新药研发和生产服务，推动全球医药健康创新。公司在亚洲、欧洲、北美等地均设有运营基地，依托独特的“CRDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来突破性的治疗方案。目前，公司的赋能平台正承载着来自全球30多个国家的约6,000家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。更多信息，请访问公司网站：www.wuxiapptec.com

WuXi AppTec Completes Second RMB1.0 Billion A-Share Repurchase Program in 2025, All Repurchased Shares to Be Cancelled

Shanghai, August 27, 2025 – WuXi AppTec Co., Ltd. (Stock codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently announced the completion of its second RMB1.0 billion A-share repurchase program in 2025 to enhance shareholder value, with all repurchased shares to be cancelled: 

On April 29, 2025, the Company's Annual General Meeting approved the RMB1.0 billion A-share repurchase and cancellation program to uphold company value and protect the interests of shareholders.

From June 26, 2025 to August 26, 2025, WuXi AppTec repurchased a total of 11,860,809 A-shares, representing 0.40% of the company’s total share capital as of August 27, 2025. The Company expects to cancel all repurchased A-shares under this program on August 28, 2025.

So far this year, WuXi AppTec has cumulatively completed RMB2.0 billion in A-share repurchases, with all repurchased shares to be cancelled. Share repurchases and cash dividends implemented this year total RMB5.84 billion, representing over 60% of the net profit attributable to the Company’s owners in 2024. 

For more information, please refer to the Company’s relevant announcement: 

Scan the QR code to view the announcement

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at https://www.wuxiapptec.com.